SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-031902
Filing Date
2023-07-06
Accepted
2023-07-06 08:15:43
Documents
14
Period of Report
2023-07-06
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20230706.htm   iXBRL 8-K 62993
2 EX-99.1 rare-ex99_1.htm EX-99.1 31811
3 GRAPHIC img45776771_0.jpg GRAPHIC 9885
  Complete submission text file 0000950170-23-031902.txt   230731

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rare-20230706.xsd EX-101.SCH 2475
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rare-20230706_pre.xml EX-101.PRE 9457
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rare-20230706_lab.xml EX-101.LAB 12806
8 EXTRACTED XBRL INSTANCE DOCUMENT rare-20230706_htm.xml XML 4516
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 231072149
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences